Advertisement

U.S. markets open in 58 minutes

S&P Futures
4,170.75
-20.75(-0.50%)
Dow Futures
34,031.00
-66.00(-0.19%)
Nasdaq Futures
12,743.75
-103.00(-0.80%)
Russell 2000 Futures
2,003.40
-4.50(-0.22%)
Crude Oil
76.04
+0.16(+0.21%)
Gold
1,929.00
-1.80(-0.09%)

Advertisement

Annovis Bio, Inc. (ANVS)

NYSE - NYSE Delayed Price. Currency in USD

Visitors trend2W10W9M

19.33

+1.28

(+7.09%)

At close: 04:00PM EST

19.39

+0.06

(+0.31%)

Pre-Market:

07:07AM EST

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bullishpattern detected

Price Crosses Moving Average

View all chart patterns

Performance Outlook

Previous Close	18.05
Open	18.04
Bid	0.00 x 1100
Ask	0.00 x 1000
Day's Range	18.04 - 19.44
52 Week Range	8.39 - 23.91
Volume	82,846
Avg. Volume	44,080

Market Cap	157.809M
Beta (5Y Monthly)	1.22
PE Ratio (TTM)	N/A
EPS (TTM)	-2.17
Earnings Date	Nov 08, 2022
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	46.00

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ANVS

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

Annovis Bio, Inc.
Daily – Vickers Top Buyers & Sellers for 10/14/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Rating
Fair Value
Economic Moat
last yearArgus Research

All

Zacks
Does Annovis Bio, Inc. (ANVS) Have the Potential to Rally 178.45% as Wall Street Analysts Expect?
The mean of analysts' price targets for Annovis Bio, Inc. (ANVS) points to a 178.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
- Wall Street Analysts Think Alibaba (BABA) Could Surge 31.5%: Read This Before Placing a Bet
  Zacks
- Wall Street Analysts See a 44.96% Upside in Udemy, Inc. (UDMY): Can the Stock Really Move This High?
  Zacks
Zacks
Are Medical Stocks Lagging McKesson (MCK) This Year?
Here is how McKesson (MCK) and Annovis Bio, Inc. (ANVS) have performed compared to their sector so far this year.
PR Newswire
Annovis Bio Announces Filing of Patent Covering the Administration of Buntanetap and Its Analogues for the Treatment of Mental Illnesses
Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing Alzheimer's and Parkinson's disease announced today the filing of a patent application that extends the breadth of its platform from neurodegenerative to neuropsychiatric indications: "Treatment of mental illness via administration of buntanetap and analogues."